OS Therapies, a Phase 2 biotech developing an off-the-shelf immunotherapy for osteosarcoma, withdrew its filing for an initial public offering on Thursday, before refiling with new terms and underwriters within hours.
The Rockville, MD-based company now plans to raise $8 million by offering 2 million shares at a proposed price of $4. The company had previously filed to offer 2 million shares at a proposed price of $5. At the revised deal size, OS Therapies will raise -20% less in proceeds than previously anticipated and command a market cap of $82 million.
The Rockville, MD-based company was founded in 2018 and plans to list on the NYSE American under the symbol OSTX. Brookline Capital Markets is now the sole bookrunner on the deal.
Osteosarcoma biotech OS Therapies withdraws and then refiles for an $8 million IPO
May 30, 2024

